184 related articles for article (PubMed ID: 21943794)
1. Hormonal therapies and meningioma: is there a link?
Cea-Soriano L; Blenk T; Wallander MA; Rodríguez LA
Cancer Epidemiol; 2012 Apr; 36(2):198-205. PubMed ID: 21943794
[TBL] [Abstract][Full Text] [Related]
2. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland.
Korhonen K; Raitanen J; Isola J; Haapasalo H; Salminen T; Auvinen A
Cancer Causes Control; 2010 Dec; 21(12):2149-56. PubMed ID: 20730482
[TBL] [Abstract][Full Text] [Related]
3. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V
J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938
[TBL] [Abstract][Full Text] [Related]
4. Risk of brain tumors associated with exposure to exogenous female sex hormones.
Wigertz A; Lönn S; Mathiesen T; Ahlbom A; Hall P; Feychting M;
Am J Epidemiol; 2006 Oct; 164(7):629-36. PubMed ID: 16835295
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy increases the risk of cranial meningioma.
Andersen L; Friis S; Hallas J; Ravn P; Schrøder HD; Gaist D
Eur J Cancer; 2013 Oct; 49(15):3303-10. PubMed ID: 23800670
[TBL] [Abstract][Full Text] [Related]
6. Exogenous hormone use and meningioma risk: what do we tell our patients?
Claus EB; Black PM; Bondy ML; Calvocoressi L; Schildkraut JM; Wiemels JL; Wrensch M
Cancer; 2007 Aug; 110(3):471-6. PubMed ID: 17580362
[TBL] [Abstract][Full Text] [Related]
7. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
8. Is there an association between meningioma and hormone replacement therapy?
Blitshteyn S; Crook JE; Jaeckle KA
J Clin Oncol; 2008 Jan; 26(2):279-82. PubMed ID: 18182668
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT
Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790
[TBL] [Abstract][Full Text] [Related]
10. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.
Gil M; Oliva B; Timoner J; Maciá MA; Bryant V; de Abajo FJ
Br J Clin Pharmacol; 2011 Dec; 72(6):965-8. PubMed ID: 21627676
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
Seaman HE; Langley SE; Farmer RD; de Vries CS
BJU Int; 2007 Jun; 99(6):1398-403. PubMed ID: 17537215
[TBL] [Abstract][Full Text] [Related]
12. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk.
Shantakumar S; Terry MB; Paykin A; Teitelbaum SL; Britton JA; Moorman PG; Kritchevsky SB; Neugut AI; Gammon MD
Am J Epidemiol; 2007 May; 165(10):1187-98. PubMed ID: 17337757
[TBL] [Abstract][Full Text] [Related]
13. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
14. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study.
Custer B; Longstreth WT; Phillips LE; Koepsell TD; Van Belle G
BMC Cancer; 2006 Jun; 6():152. PubMed ID: 16759391
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy and risk of meningioma in women: a meta-analysis.
Fan ZX; Shen J; Wu YY; Yu H; Zhu Y; Zhan RY
Cancer Causes Control; 2013 Aug; 24(8):1517-25. PubMed ID: 23702884
[TBL] [Abstract][Full Text] [Related]
16. Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk.
Schwartzbaum J; Jonsson F; Ahlbom A; Preston-Martin S; Malmer B; Lönn S; Söderberg K; Feychting M
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):643-50. PubMed ID: 15767344
[TBL] [Abstract][Full Text] [Related]
17. Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.
Muskens IS; Wu AH; Porcel J; Cheng I; Le Marchand L; Wiemels JL; Setiawan VW
Neuro Oncol; 2019 Mar; 21(4):498-507. PubMed ID: 30615143
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
19. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
Cebula H; Pham TQ; Boyer P; Froelich S
Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
[No Abstract] [Full Text] [Related]
20. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
